William Blair Issues Optimistic Forecast for DVAX Earnings

William Blair analysts have raised their Q1 2026 earnings per share (EPS) estimate for Dynavax Technologies (NASDAQ:DVAX) from $0.11 to $0.14. The consensus estimate for the full year is $0.32 EPS. The company reported $0.21 EPS for the last quarter, exceeding expectations. Despite a recent stock decline of 4%, Dynavax has a market cap of $1.24 billion and a PE ratio of -22.93. Institutional investors hold 96.96% of the stock, indicating strong institutional interest.

Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) - Analysts at William Blair boosted their Q1 2026 earnings per share (EPS) estimates for shares of Dynavax Technologies in a research note issued to investors on Thursday, November 6th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.14 for the quarter, up from their prior forecast of $0.11. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies' Q2 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.60 EPS.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The business had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million.

Get Dynavax Technologies alerts:

Other equities analysts have also issued reports about the stock. JMP Securities reiterated a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Dynavax Technologies presently has an average rating of "Hold" and a consensus price target of $24.33.

Get Our Latest Report on Dynavax Technologies

Dynavax Technologies Stock Down 4.0%

Shares of DVAX traded down $0.44 during mid-day trading on Friday, reaching $10.55. The company's stock had a trading volume of 320,078 shares, compared to its average volume of 1,979,793. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. Dynavax Technologies has a 12-month low of $9.20 and a 12-month high of $14.63. The stock has a market cap of $1.24 billion, a PE ratio of -22.93 and a beta of 1.09. The company's 50 day moving average is $10.00 and its 200 day moving average is $10.29.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers acquired 3,800 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director directly owned 35,004 shares of the company's stock, valued at approximately $378,743.28. This represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DVAX. DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies during the 1st quarter valued at $30,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,304 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Dynavax Technologies by 236.9% during the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 2,710 shares during the last quarter. LSV Asset Management acquired a new position in Dynavax Technologies in the 3rd quarter valued at about $89,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock worth $93,000 after purchasing an additional 1,226 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Should You Invest $1,000 in Dynavax Technologies Right Now?

Before you consider Dynavax Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.

While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here